Q-omics provides the consensus-scored ZSWIM6 profile across patient tissues and cancer cell-line models. ZSWIM6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZSWIM6 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ZSWIM6 RNA expression shows 20,273 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where ZSWIM6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSWIM6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSWIM6 survival associations across molecular data types. ZSWIM6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSWIM6 RNA expression–survival associations across cancer types. High ZSWIM6 expression shows unfavorable associations in STAD, ESCA, UVM, OV and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZSWIM6 RNA expression.
This table summarizes ZSWIM6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZSWIM6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSWIM6 shows lower tumor expression in COAD, THCA and READ and higher tumor expression in HNSC, KIRC and CHOL. The COAD box plot shows higher ZSWIM6 RNA expression in normal versus tumor tissue (log2 FC = −0.948, t-test p < 0.001).
This table shows molecular features associated with ZSWIM6 in patient tissues and cancer cell lines. In patient samples, ZSWIM6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSWIM6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
